Kazia Therapeutics Ltd (KZIA) ADR Each Representing 100 Ord Shares SPON

Sell:$0.77Buy:$0.83$0.01 (1.85%)

Prices delayed by at least 15 minutes
Sell:$0.77
Buy:$0.83
Change:$0.01 (1.85%)
Deal now
Prices delayed by at least 15 minutes
Sell:$0.77
Buy:$0.83
Change:$0.01 (1.85%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Kazia Therapeutics Limited is an oncology-focused drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. It designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.

Key people

John E. Friend
Interim Executive Chairman of the Board, Chief Executive Officer, Managing Director
Karen Krumeich
Chief Financial Officer
Lilischkis Ron Kimberley
Clinical & Regulatory Affairs Manager
Peng K. Leong
Chief Business Officer
Stephen Palmer
Program Director - Degenerative Diseases
Justine R. Stehn
Director - ATM Program
Anna Sandham
Company Secretary
Steven Roy Stent Coffey
Non-Executive Director
Bryce Carmine
Non-Executive Independent Director
Ebru Davidson
Non-Executive Independent Director

Key facts

  • EPIC
    KZIA
  • Location
    Australia
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US48669G2049
  • Market cap
    $5.07m
  • Employees
    12
  • Shares in issue
    22.80m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.